CARDIOGENESIS ANNOUNCES SUCCESSFUL CLINICAL APPLICATION OF PHOENIX TMR PLUS STEM CELL DELIVERY SYSTEM

Cardiogenesis Corporation, the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures announced today the first clinical surgical cardiac revascularization procedure completed on January 25, 2006 by Dr. Wan Feng, Chairman of the Department of Cardiac Surgery at The People's Hospital of Beijing University with its PHOENIX Revascularization Delivery System for precise delivery of stem cells in conjunction with Holmium.
INS News